zifeng-ai/TrialReviewBench huggingface dataset:
Study PMID 31700918 (2019)
Design: randomized control trial
Chemotherapy regimen: Epirubicin + docetaxel; epirubicin + cyclophosphamide
Time of blood collection: On days 1, 3, 5, 7, 8, 9, 10, 11, 13, 15, 17, and 21 during cycle 1 or until an absolute neutrophil count ≥ 2.0 × 109/L was reached
Primary endpoints: Duration of grade ≥ 3 neutropenia
Follow-up: Four cycles
Study PMID 31205914 (2019)
Design: randomized control trial
Chemotherapy regimen: Epirubicin + docetaxel; epirubicin + cyclophosphamide
Time of blood collection: Daily from the first day of chemotherapy to next cycle
Primary endpoints: ≥ Grade III absolute neutrophil count neutropenia, adverse events
Follow-up: Two cycles
Study PMID 30181755 (2018)
Design: randomized control trial
Chemotherapy regimen: Doxorubicin + cyclophosphamide
Time of blood collection: 1 and 2 weeks after chemotherapy
Primary endpoints: Blood cell counts, adverse events
Follow-up: Two cycles
Study PMID 30043207 (2018)
Design: randomized control trial
Chemotherapy regimen: Adriamycin/epirubicin + cyclophosphamide
Time of blood collection: Days 0, 3, 5, 7, 9, 11, 13, 17, the blood was collected after chemotherapy
Primary endpoints: Grade IV absolute neutrophil count neutropenia, adverse events
Follow-up: Two cycles
Study PMID 29230663 (2018)
Design: randomized control trial
Chemotherapy regimen: Epirubicin + cyclophosphamide; epirubicin + docetaxel; docetaxel + cyclophosphamide
Time of blood collection: Days 3, 5, 7–11, 13, 15, 17, and 21 of cycle 1, and on days 5, 7, 9, 11, 13, and 21 of subsequent cycles
Primary endpoints: Grade IV absolute neutrophil count neutropenia, adverse events
Follow-up: Four cycles
Study PMID 27709313 (2017)
Design: randomized control trial
Chemotherapy regimen: Doxorubicin + cyclophosphamide + docetaxel
Time of blood collection: not applicable
Primary endpoints: Grade IV absolute neutrophil count neutropenia, adverse events
Follow-up: Six cycles
Study PMID 25820754 (2015)
Design: randomized control trial
Chemotherapy regimen: Doxorubicin + cyclophosphamide + docetaxel
Time of blood collection: Days 3, 5, 7–11, 13, 15, 17, 21 of the chemotherapy cycle 1 for absolute neutrophil count determination, and if an ANC ≤ 1.0 × 109/L, blood samples were collected daily until absolute neutrophil count reached ≥ 2.0 × 109/L
Primary endpoints: ≥ Grade III absolute neutrophil count neutropenia, adverse events
Follow-up: One cycle
Study PMID 23677653 (2013)
Design: randomized control trial
Chemotherapy regimen: Doxorubicin + cyclophosphamide + docetaxel
Time of blood collection: not applicable
Primary endpoints: Grade IV absolute neutrophil count neutropenia
Follow-up: One cycle
Study PMID 11821454 (2002)
Design: randomized control trial
Chemotherapy regimen: Doxorubicin + docetaxel
Time of blood collection: not applicable
Primary endpoints: Grade IV absolute neutrophil count neutropenia
Follow-up: Four cycles